Objective To evaluate the clinical curative effect of Jingui-Shenqi pill combined with salvia miltiorrhiza ligustrazine injection treatment for CPHD. Methods A total of 150 patients with CPHD were randomly divided into the observation group and control group according to the medical records number, 75 patients in each group.The control group was given intravenous salvia miltiorrhiza ligustrazine injection on the basis of the conventional western medicine treatment, and the observation group taking Jingui-Shenqi pill on the basis of the control group, two weeks as a course. The New York heart association (NYHA) classification standard, heart function and blood gas analysis and lung function related indicators, and the clinical curative effect were assessed. Results The observation group total effective rate was 92.0% (69/75), the control group was 78.7% (59/75). There was statistical significance between two groups (χ2=5.842, P=0.020). After treatment, the observation group of patients with cardiac function grade I have 37 patients (49.3%), significantly more than the control group of 24 patients (32.0%), (χ2=7.368, P=0.001); After treatment, the CI (4.82 ± 1.57 L·min-1·m-2vs. 3.76 ± 1.30·min-1·m-2, t=6.542), BPPaO2 (9.86 ± 1.53 kPa vs. 8.53 ± 1.40 kPa, t=5.956), SaO2 (99.65% ± 2.83% vs. 96.03% ± 5.47%, t=7.062) in the observation group were significantly higher than those in the control group (P<0.05). The PASP (4.01 ± 0.53 kPa vs. 5.42 ± 0.83 kPa, t=4.986), PaCO2 (6.12 ± 0.36 kPa vs. 6.37 ± 0.34 kPa, t=5.024) in the observation group were significantly lower than those in the control group (P<0.05). Conclusions The Jingui-Shenqi pill combined with salvia miltiorrhiza ligustrazine injection could improve CPHD cardiopulmonary function and curative effect, compared with the conventional western medicine therapy combined with salvia miltiorrhiza ligustrazine injection treatment. Key words: Pulmonary heart disease; Jingui-Shenqi pill; Salvia miltiorrhiza ligustrazine injection; Atrial function; Clinical study